One necessary step to fend off a dystopian future of medical care without antibiotics is the development of new antibiotics. Another is improved deployment of existing ones, a feat which will take, among other things, better antibiotic susceptibility testing (AST).
MELBOURNE, Australia – Researchers at the Murdoch Children’s Research Institute in Melbourne are pushing the boundaries on creating kidney tissue from stem cells.
Researchers at the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine (KUSM) in Japan have discovered that people ages 110 or longer, the so-called supercentenarians, have elevated blood levels of CD4+ cytotoxic T lymphocytes (CTLs).
A team led by researchers at Washington State University (WSU) has developed a nanoparticle technology to deliver cell-killing drugs to shut down the overactive immune response that can cause damage or death in diseases like stroke and sepsis without affecting other cell types or compromising the immune system.
There are a pair of approved CAR T drugs, Yescarta (axicabtagene ciloleucel) from Gilead Sciences Inc. and Kymriah (tisagenlecleucel) from Novartis AG, that have been available since 2017 for a few hematological cancers, including some lymphomas and leukemias.
The discovery that thalidomide and its analogues work by inducing the degradation of transcription factors demonstrated both that protein degradation is a viable mechanism of action for therapeutic small molecules, and that it could be used to target transcription factors, which are undruggable by both biologics and traditional inhibitors.
BOSTON – Researchers presented data at The Liver Meeting 2019 and in Nature this week demonstrating that bacteriophages targeted to specific members of the microbiome could be useful in fighting two different liver diseases.
BOSTON – In a late-breaking oral presentation on the last day of The Liver Meeting 2019, Durect Corp. reported results from its phase IIa trial of DUR-928 for the treatment of alcoholic hepatitis. All 19 patients enrolled in the study survived for 28 days after treatment with DUR-928 , and all but two responded to the drug as measured by Lille scores, which is used for predicting risk of death.
BOSTON – For diagnosing nonalcoholic steatohepatitis (NASH), liver biopsy is "the reference standard," Dean Hum, president of Genfit Corp., told BioWorld. "I'm not going to call it the gold standard." Some of the reasons for denying biopsies a gold sticker are obvious. Biopsies are invasive, which makes them risky, expensive and loathed by patients and doctors alike. "In the real world, doctors don't always do biopsies – many say they very rarely do biopsies unless other data points in several directions and they need that for clarity," Gail Cawkwell told BioWorld.
RSS
